BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28901493)

  • 1. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
    Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
    Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids.
    Chiu LY; Hsin IL; Yang TY; Sung WW; Chi JY; Chang JT; Ko JL; Sheu GT
    Oncogene; 2017 Jan; 36(2):242-253. PubMed ID: 27270426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
    Zhang D; Ochi N; Takigawa N; Tanimoto Y; Chen Y; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
    Cancer Lett; 2011 Oct; 309(2):228-35. PubMed ID: 21742432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.
    Ding X; Gu Y; Jin M; Guo X; Xue S; Tan C; Huang J; Yang W; Xue M; Zhou Q; Wang W; Zhang Y
    Theranostics; 2020; 10(13):6048-6060. PubMed ID: 32483437
    [No Abstract]   [Full Text] [Related]  

  • 5. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines.
    Chiu LY; Ko JL; Lee YJ; Yang TY; Tee YT; Sheu GT
    Toxicol Lett; 2010 Feb; 192(3):408-18. PubMed ID: 19944135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
    Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
    Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
    Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
    Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.
    Monica V; Lo Iacono M; Bracco E; Busso S; Di Blasio L; Primo L; Peracino B; Papotti M; Scagliotti G
    Oncotarget; 2016 Nov; 7(47):76577-76589. PubMed ID: 27391433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
    Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
    J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
    Chen X; Yang Y; Berger I; Khalid U; Patel A; Cai J; Farwell MD; Langer C; Aggarwal C; Albelda SM; Katz SI
    Oncotarget; 2017 Apr; 8(15):24213-24223. PubMed ID: 27655645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
    Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
    Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
    Chen X; Yang Y; Katz SI
    PLoS One; 2018; 13(8):e0202384. PubMed ID: 30142195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancer.
    Yoon JY; Park CK; Choi YD; Oh IJ; Kim YC
    Thorac Cancer; 2019 Apr; 10(4):942-949. PubMed ID: 30864258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
    Kawabata S; Chiang CT; Tsurutani J; Shiga H; Arwood ML; Komiya T; Gills JJ; Memmott RM; Dennis PA
    Oncotarget; 2014 Feb; 5(4):1062-70. PubMed ID: 24658085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy.
    Hou J; Lambers M; den Hamer B; den Bakker MA; Hoogsteden HC; Grosveld F; Hegmans J; Aerts J; Philipsen S
    J Thorac Oncol; 2012 Jan; 7(1):105-14. PubMed ID: 22134068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
    Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
    Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Sun JM; Han J; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2011 Aug; 6(8):1392-9. PubMed ID: 21716147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
    Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
    Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma.
    Yang M; Fan WF; Pu XL; Liu FY; Meng LJ; Wang J
    Oncol Lett; 2014 Jan; 7(1):227-232. PubMed ID: 24348854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.